Objective
There is a troubling lack of effective pain treatments after major surgery. Especially after musculoskeletal procedures, patients experience debilitating pain now treated with opioids. Opioids provide insufficient pain relief, have many toxic side-effects, and are highly addictive. Pain and opioid-related side-effects impede early mobilisation and recovery and are the primary reasons for extended hospital stays.
SentryX is developing revolutionary drug delivery technology to extend the effects of a well-established local pain blocker called bupivacaine. Its initial use case in spine fixation surgery, Bupi-Ring, delivers bupivacaine directly to the surgical site for more than 72 hours without changing the existing surgical workflow. Non-opioid local pain relief in this critical early phase of recovery will promote early mobilisation, shorten hospital stays, prevent complications, and save costs. This project will demonstrate Bupi-Rings safety and efficacy in humans for the first time.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
You need to log in or register to use this function
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
3711 AA Austerlitz
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.